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29.3Gy  and  29.6Gy  in  stage  3/4.  Average  rectum  D2cc  
was 19.2Gy, 16.5Gy and 19.9Gy in stage 1/2 and 21.8Gy, 
24.6Gy  and  26.3Gy  for  stage  3/4.  Average  bladder  D2cc  
was  46.2Gy,  27.9Gy,  and  24.4Gy  for  stage  1/2,  and  
31.2Gy,  38.1Gy  and  35.8Gy  for  stage  3/4  (table  2). 
 
 
Conclusion  
MR    guided    BT    improves    HRCTV    dose    coverage    
dramatically. In our cohort average HRCTV D90 increased 
by more than 20Gy for stage 1/2 and more than 10GY for 
stage  3/4  disease.  Improvements  were  also  seen  in  the  
OARs; bladder D2cc more than rectal D2cc. The reduction 
in bladder dose was largest for stage 1/2 disease. The use 
of needles allowed similar dose coverage despite a large 
difference  in  the  HRCTV  volume.  The  benefits  of  image  
guided  BT  with  interstitial  needles  is  therefore  seen  in  
HRCTV  coverage  as  well  as  OAR  dose.  To  achieve  the  
EMBRACE2  tolerances,  further  reductions  in  OAR  doses,  
especially rectum, are necessary to facilitate an increase 
in  the  BT  dose  fractionation  to  28Gy  in  4  fractions  with  
EBRT dose at 45Gy in 25 fractions. This will improve with 
experience or perhaps the use of oblique needles to treat 
side wall disease more effectively.  
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Purpose or Objective  
To   report   on   the   effects   of   modulated   electro-
hyperthermia (mEHT) as a radiosensitiser on toxicity and 
local  disease  control  in  HIV  positive  cervical  cancer  
patients.  
Material and Methods  
136  participants  were  prescribed  50Gy  external  beam  
radiation,  3  doses  of  8Gy  high  dose  rate  brachytherapy  
and   cisplatin   as   a   radiosensitiser.   Participants   were   
randomised,  based  on  HIV  status,  FIGO  stage  of  disease,  
and  age,  into  a  control  group  or  study  group.  The  study  
group  received  10  mEHT  treatments  plus  the  prescribed  
chemoradiotherapy regime. Each mEHT treatment was 55 
minutes   at   a   target   power   of   130W.   HIV   positive   
participants  must  have  been  on  antiretroviral  treatment  
for  a  minimum  of  6  months  and  have  a  CD4  count  of  
above     200cells/mm3.     Participants     with     bilateral     
hydronephrosis    and    a    creatinine    clearance    below    
positive.  Complete  response  (CR)  rates  are  as  follows:  
HIV  positive  study:  67%;  HIV  negative  study:  54%;  HIV 
positive control: 57%; HIV negative control: 37%. 6 month 
survival in the HIV positive and negative study groups are 
89%  and  100%  respectively,  and  in  the  HIV  positive  and  
negative  control  groups  survival  was  84%  and  87.5%  
respectively.  
The  frequency  of  grade  4  toxicities  on  treatment  was  
higher  in  the  HIV  positive  groups  compared  to  the  HIV  
negative  groups.  However  the  frequency  of  grade  3  
toxicities  was  highest  in  the  HIV  negative  control  group.  
The  most  common  toxicity  was  bladder.  1  Grade  3  skin  
toxicity was reported in both HIV positive groups and 1 in 
the HIV negative control group.  
At  3  months,  skin  and  bladder  toxicity  was  higher  in  the  
HIV  positive  study  group  than  the  HIV  negative  study  
group,  with  2  grade  4  bladder  toxicities  in  the  HIV  
positive  study  group.  The  HIV  negative  control  group  
reported  the  highest  frequency  of  bladder  toxicities:  3  
grade  3  and  4  grade  4  toxicities.  There  were  no  grade  3  
or  4  lower  GI/rectal  toxicities  in  the  study  group  and  2  
grade  4  toxicities  in  both  control  groups  (HIV  negative  
and positive). 
Conclusion  
Early results do not show an obvious pattern/relationship 
in the frequency/severity of toxicities in the HIV positive 
groups compared to the HIV negative groups, irrespective 
of  the  administration  of  mEHT.  Overall  the  local  disease  
control is improved in the study group. There is a higher 
CR rate in HIV positive groups of each arm. The 6 month 
survival does not show the same pattern of improvement 
in the HIV positive groups. Survival at 6 months is higher 
in  the  study  group.  The  significance  of  this  will  be  
confirmed in a larger sample and longer follow up. 
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Purpose or Objective  
The  association  between  cervical  cancer  and  HIV  is  well  
known, being one of the defining conditions of AIDS, and 
one  of  the  most  common  neoplasms  related  to  this  
disease. 
In addition, the evolution of HIV disease and response to 
treatment seems to be modified in this group of patients, 
having  the  tumor  a  more  aggressive  behavior  and  worse  
prognosis compared to non-HIV population. 
Objective:   Describe   evolution   of   HIV   patients   with   
cervical cancer treated with radiotherapy in our center. 
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